The dawn phenomenon revisited: implications for diabetes therapy
- PMID: 16033737
- DOI: 10.4158/EP.11.1.55
The dawn phenomenon revisited: implications for diabetes therapy
Abstract
Objective: To summarize current data on the magnitude, prevalence, variability, pathogenesis, and management of the dawn phenomenon in patients with diabetes mellitus.
Methods: On the basis of the pertinent available literature and clinical experience, we propose a quantitative definition of the dawn phenomenon, discuss potential pathogenic mechanisms, and suggest management options.
Results: The "dawn phenomenon" is a term used to describe hyperglycemia or an increase in the amount of insulin needed to maintain normoglycemia, occurring in the absence of antecedent hypoglycemia or waning insulin levels, during the early morning hours. To be clinically relevant, the magnitude of the dawn increase in blood glucose level should be more than 10 mg/dL or the increase in insulin requirement should be at least 20% from the overnight nadir. Controversy exists regarding the frequency, reproducibility, and pathogenesis of the dawn phenomenon. Approximately 54% of patients with type 1 diabetes and 55% of patients with type 2 diabetes experience the dawn phenomenon when the foregoing quantitative definition is used. The most likely pathogenic mechanism underlying the dawn phenomenon is growth hormone-mediated impairment of insulin sensitivity at the liver and muscles. The exact biochemical pathways involved are unknown. Therapeutic decisions aimed at correcting fasting hyperglycemia should take into account the variability and magnitude of the dawn phenomenon within individual patients. Successful insulinization appears to minimize the effects of the dawn phenomenon. Currently, no subcutaneous depot preparation of insulin exists that is capable of mimicking the basal insulinsecretion of the healthy pancreas.
Conclusion: Increases in the bedtime doses of hypoglycemic agents with nighttime peaks in action may correct early morning hyperglycemia but be associated with undesirable nocturnal hypoglycemia. Targeted continuous subcutaneous insulin infusion programming can facilitate the prevention of early morning hyperglycemia in selected patients.
Similar articles
-
Nocturnal blood glucose control in type I diabetes mellitus.Diabetes Care. 1993 Dec;16 Suppl 3:71-89. doi: 10.2337/diacare.16.3.71. Diabetes Care. 1993. PMID: 8299480 Review.
-
Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.Diabetes Technol Ther. 2002;4(5):595-605. doi: 10.1089/152091502320798213. Diabetes Technol Ther. 2002. PMID: 12450440 Clinical Trial.
-
Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.Endocr Pract. 2012 Jul-Aug;18(4):558-62. doi: 10.4158/EP12042.OR. Endocr Pract. 2012. PMID: 22548951 Clinical Trial.
-
Analysis of Prevalence, Magnitude and Timing of the Dawn Phenomenon in Adults and Adolescents With Type 1 Diabetes: Descriptive Analysis of 2 Insulin Pump Trials.Can J Diabetes. 2020 Apr;44(3):229-235. doi: 10.1016/j.jcjd.2019.08.003. Epub 2019 Aug 14. Can J Diabetes. 2020. PMID: 31630987
-
Fasting hyperglycemia: etiology, diagnosis, and treatment.Diabetes Technol Ther. 2004 Aug;6(4):525-33. doi: 10.1089/1520915041705910. Diabetes Technol Ther. 2004. PMID: 15321011 Review.
Cited by
-
Akkermansia muciniphila supplementation improves glucose tolerance in intestinal Ffar4 knockout mice during the daily light to dark transition.mSystems. 2023 Oct 26;8(5):e0057323. doi: 10.1128/msystems.00573-23. Epub 2023 Oct 3. mSystems. 2023. PMID: 37787527 Free PMC article.
-
Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.J Clin Endocrinol Metab. 2024 Jul 12;109(8):1984-1995. doi: 10.1210/clinem/dgae088. J Clin Endocrinol Metab. 2024. PMID: 38373265 Free PMC article. Clinical Trial.
-
Closed-loop insulin delivery in type 1 diabetes.Endocrinol Metab Clin North Am. 2012 Mar;41(1):105-17. doi: 10.1016/j.ecl.2011.12.003. Endocrinol Metab Clin North Am. 2012. PMID: 22575409 Free PMC article. Review.
-
Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices.Diabetes Care. 2014;37(5):1184-90. doi: 10.2337/dc13-2066. Diabetes Care. 2014. PMID: 24757225 Free PMC article.
-
Insulin Delivery Hardware: Pumps and Pens.Diabetes Technol Ther. 2021 Jun;23(S2):S32-S45. doi: 10.1089/dia.2021.2503. Diabetes Technol Ther. 2021. PMID: 34061635 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical